Lack of appetite: the only indication where research contradicts common opinion

• How much evidence. 2 works from 2021 to 2022, all listed in the table below along with the model.
• What was not shown. This is the only indication described here where the evidence goes directly against common belief. The meta-analysis found no significant improvement in appetite, and in one comparison, the quality of life of those taking cannabinoids was worse.
• What you won’t find here. Dosage recommendations or strain indications. The choice is made by the attending physician, and hemp flower is a raw material dispensed only by prescription.
• How to read this. The result of a study on rodents or in cell culture does not directly transfer to a patient taking flower, and the column with the model indicates what the work was actually about.

What do studies say about cannabis in the absence of appetite?

No improvement was shown.

This same work separately compared quality of life, this time based on moderate quality evidence, and the result was unfavorable for the studied preparations: minus 0.25 with a range from minus 0.43 to minus 0.07. Improvement in appetite was reported by patients in non-randomized studies.

This is the only indication described here where the evidence goes directly against common belief. The meta-analysis found no significant improvement in appetite, and in one comparison, the quality of life of those taking cannabinoids was worse than in the control group. Improvement in appetite appears in patient reports from non-randomized studies, where the expectation of effect was not separated from the preparation itself. The nutritional guideline does not recommend cannabinoids for this indication, and after twenty years of research, there is still no basis to change that.

Where does the belief that cannabis stimulates appetite come from?

From observations where no one separated expectation from the preparation. Increased appetite after cannabis has been reported for decades, but in the material collected for cancer cachexia, such reports come from non-randomized studies, where both the patient and the researcher know what was administered.

The physiology itself is not disputed here. Type 1 cannabinoid receptors are densely distributed in the hypothalamus and the reward system, and stimulation of this pathway shifts the signaling of hunger and satiety. However, from such a description, it does not follow that in a person suffering from cancer cachexia, it will translate into food intake. The mechanism suggests that something is possible. A randomized study indicates whether it happened more often than in the control group.

The discrepancy between the two layers of the same review is instructive. Non-randomized studies provided reports of improvement, randomized studies did not confirm this improvement, and the quality of life comparison was unfavorable for cannabinoids. When the result depends on how the patient assesses their own appetite, the mere knowledge of having taken the preparation is enough for the assessment to shift. Hence, ravenous hunger is a cultural certainty, while in a clinical study, it is not visible. This same discrepancy is also often visible in other areas of medicine wherever the endpoint is a feeling reported by the patient, rather than a quantity measured by a device.

What strain characteristics matter here?

None. In both reviews, preparations were studied based on the content of active substances, not the name of the cultivar: synthetic derivatives of tetrahydrocannabinol and extracts with a defined proportion of components. There is no work that randomly assigns patients to two strains and compares their effect on appetite or body weight.

What can be said about the raw material itself concerns the chemotype, meaning which phytocannabinoid predominates in a given registration position. Positions with a predominance of tetrahydrocannabinol, balanced positions, and those with a predominance of cannabidiol are often treated separately in the literature because they differ in their action profile. However, this does not turn the chemotype into a criterion for selection in appetite loss: for this indication, the starting point remains negative regardless of which compound predominates.

The terpene profile is an even weaker criterion. The composition of volatile components is sometimes provided by two independent sources, which can give different information for the same position, and none of the studies on appetite recorded the profile of the provided raw material. Therefore, linking terpenes to appetite would be adding a link that is not present in this material. Individual volatile compounds are dedicated separate pages in this comparison, for example, the description of limonene, and there it states what is known about them.

What does the doctor decide, and what does the patient?

The attending physician decides everything related to treatment. Hemp flower is a pharmaceutical raw material dispensed by prescription in the Rpw category, so neither the indication, nor the dosage, nor the route of administration is a matter of choice in the store. The patient brings to this conversation a description of their symptoms and the course of previous treatment.

In the case of appetite loss, determining the cause precedes everything else. Weight loss can be a result of the underlying disease, cancer treatment, pain, swallowing disorders, or low mood, and each of these causes has its own management. Nutritional care has guidelines based on evidence, and cannabinoids do not have recommendations in them.

On the patient’s side remains observation and its reliable communication. Recording how much one manages to eat, how body weight changes, and what symptoms occur after taking the preparation is information that the doctor cannot reconstruct from documentation. Tolerance to the preparation is often a separate question from efficacy, as the evidence of efficacy is negative here, and symptoms occur independently of it.

A separate issue is the method of dispensing. A prescription for a raw material from the Rpw category is fulfilled at a pharmacy, and the availability of individual positions changes over time with decisions on approval and what the manufacturer happens to import. A person reading a description of a strain from a year ago may therefore have before them a position that is no longer available on the market, and this is also a conversation to be had with the doctor, not a determination to be made independently.

What adverse effects have been reported in studies on this indication?

Reports of adverse effects are collected for medicinal products with a batch number, not for the name of the strain, so the following pertains to hemp flower as a group of raw materials. The most common reports include dry mouth, red eyes, and increased heart rate. Less frequently reported are dizziness upon rapid standing, daytime drowsiness, and transient worsening of short-term memory, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. The frequencies of these symptoms are not provided numerically, as public compilations for hemp flower in Poland do not separate them by individual products.

For the nutritional indication, one more thing is important. Some symptoms reported after cannabinoids affect the same area as the symptom that would be alleviated: daytime drowsiness or dry mouth do not facilitate eating. In the quality of life comparison, the group taking cannabinoids performed worse than the control group, and this is a statistically significant result, going in the opposite direction to what was expected.

How long does the effect last and what does it depend on?

On the route of administration, not the name of the strain. In the case of appetite loss, this has practical implications, as a meal is an event at a specific time, and an ingested preparation and a vaporized preparation distribute their effects over time quite differently. The following ranges are described for the route of administration, not for a single pharmacy position.

The route of administration determines the course more than the strain itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, intensity increases for another ten to thirty minutes, and the whole effect wears off within two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are waited for from half an hour to two, and the episode lasts six, sometimes eight hours. Hence the most common mistake with oral administration: someone who thinks nothing is happening after thirty minutes and adjusts the dose will receive both doses at once. The above ranges describe the route of administration, not this strain; pharmacokinetic studies for a single cultivar have not been published.

For the nutritional indication, caution arises from transferring results. The works collected in both reviews were primarily based on preparations taken orally, so extending their results to vaporization is a guess, not a conclusion.

Is mere increased appetite enough to stop weight loss?

No. Cancer cachexia is a metabolic syndrome in which weight loss and muscle loss occur despite food intake, so mere improvement in appetite does not resolve the issue. Therefore, reviews assess not only appetite but also body weight and quality of life, and only the complete set of these points says something about the indication.

This difference explains why the results of reviews may be perceived as contradictory to experience. Someone who ate more than usual after the preparation is correct about their own evening. The point assessed in the study is different: whether in the group taking cannabinoids, the average change in appetite exceeded the change in the control group throughout the observation period. The answer is: it did not exceed.

The scope of this material is narrow. Both works concern cancer patients, so appetite loss due to other diseases, in the elderly, or with eating disorders was not covered in them. The conclusion does not extend beyond the population in which it was obtained, and outside of it, there is simply no data. This does not mean that cannabinoids act differently in those situations. It only means that no one has checked that in such collected material, and transferring a negative result can be as risky as transferring a positive one.

How to read strain descriptions that link them to appetite?

In such a way that the strain description cannot promise what has not been confirmed. Comparisons are sometimes labeled with an indication, and this label comes from sales descriptions and user reports, not from clinical studies. The value of such a description ends with the characterization of the raw material itself and who supplies it.

What can be verified at the source has a different nature: registration name, manufacturer, and declared content of active substances. Such data is collected in the current list of medical marijuana strains maintained on this site, updated when the availability of positions in pharmacies changes.

Beyond the nutritional indication, there are other axes of this comparison: separate pages describe the state of evidence for sleep disorders and chronic pain. The list of positions with flower in this store is a catalog of the assortment and does not refer to any indication.

It is worth distinguishing between two types of statements that stand next to each other in such descriptions. A statement about the raw material can be verified: the registration name comes from the document allowing the position to be marketed, and the content of active substances from the manufacturer’s declaration. A statement about the effect requires a study in which someone administered this position to patients and compared it with a control group. For appetite loss, no such study exists for any strain, so every statement about the effect is added, not measured.

Frequently asked questions

Do cannabis stimulate appetite?

Randomized studies have not confirmed this. In the meta-analysis of cancer cachexia, the change in appetite in the group taking cannabinoids did not differ significantly from the control group, and improvement is often reported in non-randomized studies, where the expectation of effect was not separated from the preparation.

Can a doctor prescribe hemp flower for lack of appetite?

The indication is determined by the attending physician, and the raw material is dispensed by prescription in the Rpw category. This text describes the state of evidence and does not replace such a conversation. The nutritional guideline in oncology does not recommend cannabinoids for this indication.

Which strain works best for appetite?

No strain has been tested for this purpose. The works collected in both reviews concerned preparations described by the content of active substances, not the names of cultivars, so comparing strains with each other has no basis in this material.

Where does the belief in ravenous hunger after cannabis come from?

From common observations and from studies where no one concealed the assignment to groups. Receptor physiology describes a possible mechanism, but the mechanism is not the result: checking in a randomized system did not show improvement.

Do cannabinoids stop weight loss in cancer?

The collected evidence does not show this. Reviews did not show improvement in body weight or amount of food intake, and in the quality of life comparison, the result was unfavorable for cannabinoids compared to the control group.

Do the studies on appetite indicate anything about adverse effects?

Reports appeared in nine out of ten included works, but in randomized studies, they did not differ significantly from the control group. Frequencies for the raw flower from this material cannot be read.

Do these results also apply to people without cancer?

No. Both works involve cancer patients, so appetite loss from other causes remains outside their scope, and this material does not provide data for it.

This material is for informational purposes only and does not replace medical advice or constitute a recommendation for the use of any preparation. Editorial team of ubucha.pl